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ABSTRACT: The early stages of nonalcoholic fatty liver disease
(NAFLD) are characterized by the accumulation of fat in the liver
(steatosis). This can lead to cell injury and inﬂammation resulting in
nonalcoholic steatohepatitis (NASH). To determine whether lipid
proﬁling of liver tissue can identify metabolic signatures associated
with disease presence and severity, we explored liquid extraction
surface analysis mass spectrometry (LESA−MS) as a novel
sampling tool. Using LESA−MS, lipids were extracted directly
from the surface of ultrathin slices of liver tissue prior to detection
by high-resolution mass spectrometry (MS). An isotopically labeled
internal standard mix was incorporated into the extraction solvent
to attain semiquantitative data. Data mining and multivariate
statistics were employed to evaluate the generated lipid proﬁles and
abundances. With this approach, we were able to diﬀerentiate healthy and NAFLD liver in mouse and human tissue samples,
ﬁnding several triacylglyceride (TAG) and free fatty acid (FFA) species to be signiﬁcantly increased. Furthermore, LESA−MS
was able to successfully diﬀerentiate between simple steatosis and more severe NASH, based on a set of short-chain TAGs and
FFAs. We compared the data obtained by LESA−MS to that from liquid chromatography (LC)−MS and matrix-assisted laser
desorption ionization MS. Advantages of LESA−MS include rapid analysis, minimal sample preparation, and high lipid coverage.
Furthermore, since tissue slices are routinely used for diagnostics in clinical settings, LESA−MS is ideally placed to complement
traditional histology. Overall LESA−MS is found to be a robust, fast, and discriminating approach for determining NAFLD
presence and severity in clinical samples.
Nonalcoholic fatty liver disease (NAFLD) is stronglyassociated with obesity, type 2 diabetes, and insulin
resistance.1 With the global epidemic of obesity, NAFLD is
becoming an increasingly important problem, particularly in
Western countries where it is currently the primary cause of
liver disease.2−4 NAFLD is considered to be a disease spectrum,
from “simple” steatosis characterized by the accumulation of
ectopic fat in the liver, to more serious conditions, including
nonalcoholic steatohepatitis (NASH), cirrhosis, and hepato-
carcinoma.5,6 However, it is not possible to predict disease
progression on an individual basis, and so there is a great need
to identify biomarkers of disease stage and to elucidate the
underlying mechanisms for disease progression.7−11
Lipidomics approaches are ideally suited for the character-
ization of NAFLD pathology.12,13 Increased triacylglycerides
(TAG), important lipids for energy storage, are an early
signature of the disease. Furthermore, oxidation of lipids
containing unsaturated fatty acids is implicated in the
pathogenesis of NASH, which is characterized by hepatocellular
damage, inﬂammation, and ﬁbrosis.14 Previously, we studied
mouse and human NAFLD, using mass spectrometry imaging
(MSI) and liquid chromatography−mass spectrometry (LC−
MS).12 Using MSI, we found that lipid species had speciﬁc
spatial distributions within the liver which were lost with
disease progression. We further established that lipid proﬁles,
determined by LC−MS, could distinguish samples associated
with NAFLD from liver samples of healthy animals. These
experiments were performed on extracts from homogenized
liver tissue. In this study, we sought to determine whether a
novel surface sampling tool, liquid extraction surface analysis
(LESA), could distinguish hepatic lipid proﬁles at diﬀerent
stages of NAFLD from ultrathin tissue slices.
LESA enables analytes to be directly sampled from tissue
sections by means of a solvent droplet, which forms a liquid
microjunction with the tissue surface.15,16 Analytes are
dissolved in the droplet, which is then aspirated and directly
infused into a mass spectrometer. Coupling LESA to MS
therefore provides a detailed readout of the chemical
composition of the tissue region sampled. Recent applications
for LESA−MS include the analysis of ﬁngerprints,17 detection
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of speciﬁc proteins from dried blood spots and liver tissue,18,19
and distinguishing lung tumors driven by diﬀerent oncogenes.20
While LESA−MS has been previously applied to biological
tissue analysis, it typically provides only relative quantitation.
Due to the complexity of biological samples, reporting relative
changes in species between treatment groups does not always
provide accurate information on whether speciﬁc analytes are
signiﬁcantly increased (or decreased) by a treatment or disease
process. A particular challenge for quantitation is how best to
incorporate an internal standard (IS) into the workﬂow. One
way to achieve this is to include an IS mix in the extraction
solvent.21 However, it is not clear whether lipid extraction via a
liquid microjunction is suﬃciently reproducible to enable
diﬀerentiation of complex biological and clinical samples, such
as those from patients at diﬀerent stages of NAFLD.
Here, using mouse models of NAFLD and human clinical
samples, we establish changes to the lipid proﬁle with disease
presence and severity in tissue slices. Lipids were extracted in
situ from sections of liver tissue using LESA and detected using
high-resolution MS. An isotopically labeled standard mix,
spanning multiple lipid classes, was incorporated into the LESA
extraction solvent, in order to provide semiquantitative results.
Overall we found the lipid signature changes with onset and
progression of NAFLD, and in particular signiﬁcant increases in
monounsaturated fatty acids (MUFA) and TAGs containing
shorter chain fatty acids were found in NASH, compared to
simple steatosis. We further compare LESA−MS to LC−MS
and matrix-assisted laser desorption ionization (MALDI)-MSI
and highlight several advantages of LESA−MS over traditional
methods.
■ MATERIALS AND METHODS
Animal Study. Five-week old male ob/ob (N = 6) and wild-
type (WT, C57BL6/J strain, N = 6) mice were fed either a
regular chow (RC) or high-fat (HF) diet for a period of 12
weeks. Dietary composition is described in Table S1 and
detailed elsewhere.22 Mice were euthanized prior to a rapid
dissection of liver tissue, which was snap-frozen in liquid
nitrogen and stored at −80 °C. Serum was additionally
collected, in order to perform liver function tests. All animal
protocols were approved by the U.K. Home Oﬃce and the
University of Cambridge Animal Welfare and Ethical Review
Board and carried out by a personal license holder.
Human Samples. Nine human wedge biopsy samples were
obtained from the Human Research Tissue Bank, at
Addenbrooke’s Hospital, Cambridge (Cambridgeshire 2
Research Ethics Committee, NRES 11/EE/0011). Samples
were collected from living donors undergoing assessment;
following protocols used in the Liver Clinic of Addenbrooke’s
Hospital, tissue was rapidly frozen following collection. Patients
were selected with the following exclusion criteria: heavy
alcohol consumption, hepatitis B and C, HIV, Wilson’s disease,
autoimmune hepatitis, hepatoxic medication, α-1-antitrypsin
deﬁciency. Samples were scored23 by a histopathologist for
steatosis, ballooning, inﬂammation, ﬁbrosis and diagnosed as
normal (N = 3), simple steatosis (N = 3), or NASH (N = 3).
LESA−MS. Using a cryostat, 12 μm frozen sections were
prepared on glass microscope slides, for mouse and human liver
samples embedded in Tissue-Tek OCT. Sections were air-
dried, and lipids were extracted from sections using LESA at
multiple user-deﬁned points across the tissue surface. LESA
extraction solvent consisted of 1:2:4 chloroform/methanol/2-
propanol with 10 mM ammonium acetate; 0.8 μL of this
solvent was dispensed onto tissue surface and incubated for 2.5
s. Analytes extracted from the surface were infused using a
Triversa Nanomate (Advion BioSciences, Ithaca, NY), with
capillary voltage 1.1 kV, 0.3 gas ﬂow for 1 min into an LTQ
Orbitrap Elite (Thermo Fisher Scientiﬁc, Hemel Hempstead,
U.K.). Spectra were acquired in both positive and negative
mode, from 200 to 1000 m/z at a resolution of 60 000. Lipid
identity was performed by accurate mass using in-house
software and conﬁrmed using the Lipid Maps database.24 The
predominant fatty acid composition was determined for
selected lipids by tandem MS using collision-induced
dissociation (CID) in the linear ion trap with normalized
collision energy of 35%.
For semiquantitative experiments, the LESA extraction
solvent consisted of 25 μg/mL IS mix in 1:2:4 chloroform/
methanol/2-propanol with 10 mM ammonium acetate. The
mix included the following: N-palmitoyl-d31-D-erythro-sphingo-
sine (C16-d31 ceramide), pentadecanoic-d29 acid (15:0-d29
FFA), heptadecanoic-d33 acid (17:0-d33 FFA), eicosanoic-d39
acid (20:0-d39 FFA), tetradecylphosphatidylcholine-d42 (14:0-
d29 LPC-d13), 1-palmitoyl(d31)-2-oleyl-sn-glycero-3-phosphati-
dylcholine (16:0-d31−18:1 PC), 1-palmitoyl(d31)-2-oleyl-sn-
glycero-3-phosphoethanolamine (16:0-d31−18:1 PE), 1-palmi-
toyl-d31−2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (so-
dium salt) (16:0-d31−18:1 PG), 1-palmitoyl-d31−2-oleoyl-sn-
glycero-3-phosphoinositol (ammonium salt) (16:0-d31−18:1
PI), N-palmitoyl(d31)-D-erythro-sphingosylphosphorylcholine
(16:0-d31 SM), glyceryl tri(pentadecanoate-d29) (45:0-d87
TAG), glyceryl-tri(hexadecanoate-d31) (48:0-d93 TAG) (Avanti
Polar Lipids Inc., U.S.A.).
LC−MS. Lipids were extracted using the Folch method.25 An
amount of 20 mg of liver tissue was homogenized in 400 μL of
deionized water using a TissueLyser (Qiagen Ltd., Manchester,
U.K.). Chloroform/methanol (2:1, 1 mL) was added, and the
samples thoroughly mixed. The layers were separated by
centrifugation (12 000g, 10 min). The extraction was
performed in duplicate, with resulting organic extracts
combined, dried under nitrogen, reconstituted in chloroform/
methanol (2:1, 300 μL), and diluted 1:50 in 2-propanol/
acetonitrile/water (2:1:1). Samples were analyzed by LC−MS
using an Accela Autosampler coupled to a LTQ Orbitrap Elite
(Thermo Fisher Scientiﬁc, Hemel Hempstead, U.K.). Sample
(5 μL) was injected onto an Acuity C18 BEH column (Waters
Ltd., Warrington, U.K.; 50 × 2.1 mm, 1.7 μm) with a column
temperature of 55 °C. Mobile phase A was acetonitrile/water
60:40, and mobile phase B was 2-propanol/acetonitrile 90:10,
both of which had 10 mM ammonium acetate (negative ion
mode), or 10 mM ammonium formate (positive ion mode)
added. A gradient run was used (Table 1) at a ﬂow rate of 0.5
mL/min. The heated electrospray ionization source was at 375
°C, the desolvation temperature was 380 °C, and desolvation
gas ﬂow 40 arbitrary units. Spectra were acquired in positive
and negative ion mode in the range of 200−1000 m/z at 60 000
resolution.
MALDI-MSI. Matrix solutions (10 mg/mL) of 2,5-
dihydroxybenzoic acid (DHB; Sigma-Aldrich, St. Louis, MO;
positive ion mode) or 2,4,6-trihydroxyacetophenone (THAP;
Sigma-Aldrich; negative ion mode) in 85:15 methanol/water
(v/v) with 0.1% triﬂuoroacetic acid were administered to the
tissue surface using a Suncollect MALDI spotter (KR Analytical
Ltd., Cheshire, U.K.). Whole tissue slice imaging experiments
were carried out using a MALDI LTQ Orbitrap XL (Thermo
Fisher Scientiﬁc, Hemel Hempstead, U.K.) at 50 μm step
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increments. Spectra were acquired in positive and negative ion
mode, from 200 to 1000 m/z at 60 000 resolution.
Data Processing. Data from LESA−MS and LC−MS
experiments were converted to mzML format, and data from
MALDI-MSI converted to imzML format for processing.26
Using an in-house R script, ions were retained above a
threshold intensity and the mass-to-charge (m/z) ratio of ions
detected were summed across integral regions of 5 ppm to
allow for alterations in m/z mass accuracy across the
experiment (“binning”). Lipid identiﬁcation by accurate mass
is achieved by searching against a library of lipid m/z ratios
computed for all combinations of common fatty acids, lipid
head-groups, and anticipated adducts in each ionization mode.
Possible adducts in LESA−MS and LC−MS were [M + H]+,
[M + Na]+, [M + NH4]
+ in positive ion mode and [M − H]−,
[M + OAc]− in negative ion mode. Possible adducts in
MALDI-MSI were [M + H]+, [M + Na]+, [M + K]+ in positive
ion mode, and [M − H]−, [M − Cl]− in negative ion mode.
Principal components analysis (PCA) and orthogonal
projection to latent structures discriminant analysis (OPLS-
DA) models27,28 were constructed using SIMCA 14 (Umetrics,
Sweden), following normalization to the total ion count, and
Pareto scaling.29 Semiquantitative experiments yielded analyte/
IS intensity ratios; group means were compared using ANOVA
with Bonferroni correction for multiple comparisons.
■ RESULTS AND DISCUSSION
In Situ Lipid Proﬁling of Liver Tissue Using LESA−MS.
WT and ob/ob mice were fed either a regular chow (RC) or
high-fat (HF) diet in order to induce NAFLD. Ob/ob mice are
a commonly used genetic model in diabetes and obesity
research.30,31 These mice are unable to produce the satiety
hormone leptin, and consequently develop obesity and fatty
liver.32 WT mice develop NAFLD when maintained on a HF
diet,31 while WT mice on a RC diet remained lean, and were
used as controls. Body weights and steatosis in the liver
increased in the order WT-RC < WT-HF < ob/ob-RC ≈ ob/ob-
HF. Elevated liver enzymes (alkaline phosphatase, alanine
transaminase, aspartate transaminase) in both ob/ob groups
indicate inﬂammation of the liver, with the highest levels noted
for mice in ob/ob-RC group (Figure 1A).
In order to determine whether LESA−MS could be used to
distinguish the above groups by their lipid proﬁles, lipids were
extracted from the surface of tissue sections (Figure 1B). Five
diﬀerent points across each of the tissue sections were sampled,
and spectra compared for control and NAFLD liver (Figure
1C−D). Typically, more than 500 lipids were identiﬁed from
>10 lipid classes, including TAGs, diacylglycerides (DAG),
ceramides, cholesteryl esters, phosphatidylcholines (PC),
phosphatidylinositols (PI), phosphatidylethanolamines (PE),
phosphatidylglycerols (PG), sphingomyelins (SM), and free
Table 1. Chromatography Gradient Composition for
Lipidomics Open Proﬁling by LC−MS
time (min) mobile phase A (%) mobile phase B (%)
0 60 40
0.8 57 43
0.9 50 50
4.8 46 54
4.9 30 70
5.8 19 81
8 1 99
8.5 1 99
8.6 60 40
10 60 40
Figure 1. Liquid extraction surface analysis (LESA)−MS enables in situ sampling of fatty liver tissue. Wild-type (WT) and ob/ob mice were fed a
regular chow (RC) or high-fat (HF) diet. Serum alkaline phosphatase (AP), alanine transaminase (ALT), and aspartate transaminase (AST) levels
(indicators of liver injury and inﬂammation) were all elevated in ob/ob-RC and ob/ob-HF groups (A). Data show mean ± standard error of mean
(SEM); * P < 0.05, ** P < 0.01, *** P < 0.001 (ANOVA with Bonferroni correction). Tissue sections from the mouse study were prepared for
analyses by LESA−MS (B). Five diﬀerent points across the tissue surface were sampled; a pipette tip brings a droplet of solvent in contact with the
tissue to form a liquid microjunction. Lipids are dissolved in the droplet, which is aspirated and infused into the MS. Multiple spectra from diﬀerent
tissue sections were compared using multivariate statistics. Example LESA−MS spectra in positive and negative ion modes for control (WT-RC; C)
and NAFLD (ob/ob-RC; D) mouse liver tissue. Major lipid classes identiﬁed in positive ion mode included diacylglycerides (DAG), triacylglycerides
(TAG), and phosphatidylcholines (PC). In negative ion mode, the major lipid classes identiﬁed were free fatty acids (FFA),
phosphatidylethanolamines (PE), phosphatidylglycerols (PG), phosphatidylinositols (PI), and PCs.
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fatty acids (FFA). Major lipid classes identiﬁed in positive ion
mode included ammoniated adducts of DAGs and TAGs and
protonated PCs. In negative ion mode, the major lipid classes
identiﬁed were deprotonated FFAs, PEs, PGs, PIs, and acetate
adducts of PCs.
Notable diﬀerences were observed in the lipid proﬁles of
control and NAFLD liver tissue. The most striking observation
was the relative increase in TAGs compared to PCs in NAFLD
liver (Figure 1C−D). For instance, in positive ion mode, the
most abundant ion for WT-RC liver was m/z 758.571
(PC(34:2) [M + H]+; Figure 1C). In contrast, the most
prominent ion in ob/ob-RC liver was m/z 876.801 (TAG(52:2)
[M + NH4]
+; fatty acid composition 16:0/18:1/18:1; Figure
1D, Table 2). In negative ion mode, the most abundant ion in
WT-RC and ob/ob-RC liver was m/z 279.234 (FFA(18:2) [M
− H]−) and m/z 281.249 (FFA(18:1) [M − H]−), respectively
(Figure 1C−D). While relatively high-intensity m/z 327.234
(FFA(22:6) [M − H]−) was observed in control liver, this ion
was of relatively low abundance in NAFLD.
Lipid Proﬁles Diﬀerentiate Healthy and Diseased
Liver in a Mouse Model of NAFLD. We used the hepatic
lipid proﬁles, determined by LESA−MS, to discriminate the
four sample groups (WT-RC, WT-HF, ob/ob-RC, ob/ob-HF;
H&E stained sections in Figure 2A). A PCA model was
constructed (Figure 2B), in which the four groups can be
clearly distinguished (R2 = 0.91, Q2 = 0.95). The ﬁrst principal
component (x-axis) diﬀerentiated the disease state (NAFLD or
control), while the second principal component (y-axis)
separated mice on the two diﬀerent diets (RC or HF). The
corresponding loadings plot revealed the lipid species most
important for discriminating the groups (Figure 2C). A relative
increase in PCs and saturated fatty acids [FFA(16:0),
FFA(18:0)] was observed in the WT-RC group, compared to
the three NAFLD groups which had increased TAGs. The ob/
ob-RC group had the largest relative increase in MUFA
[FFA(18:1), FFA(16:1)]. In contrast, the HF-fed mice had a
relatively increase in lipids containing polyunsaturated fatty
acids [e.g., TAG(52:4), TAG(54:4), FFA(18:2)] compared to
the groups fed a RC-diet (Figure 2C, Table 2), in line with the
composition of the diet (Table S1).
An OPLS-DA model was constructed to compare the WT-
RC group with the combined NAFLD groups (Figure 2D; R2 =
0.80, Q2 = 0.97, CV-ANOVA p < 0.001). The associated S-
plot27 combines the modeled covariance and correlation from
the OPLS-DA model in a scatter plot (Figure 2E). This enables
the determination of the most important and reliable lipid
species for distinguishing the two groups (right upper and left
lower quadrants for control and NAFLD liver, respectively).
This highlighted the relative increase in PCs and FFA(22:6) for
nonfatty liver compared to NAFLD, which was characterized by
relative increases in TAG and MUFA [FFA(18:1)].
Semiquantitative Experiments Reveal Signiﬁcantly
Increased Lipids in NAFLD. Increased TAGs are a well-
known characteristic of fatty liver disease. However, the
apparent relative decrease in PCs noted in NAFLD liver
compared to the control group may be due to an actual
decrease in PC content, an increase in TAGs, or a combination
of the two. Furthermore, the increased TAGs in NAFLD
samples may give rise to increased matrix suppression
compared to samples with lower concentration of TAGs. In
Table 2. Signiﬁcantly Increased Lipid Species Identiﬁed by LESA−MS in Mouse and Human NAFLD
lipid species m/z theor m/z
theor exact
mass
mass accuracy
(ppm) fatty acid composition
conﬁrmed by
MS/MS diagnostic ions lipid increaseda
Mouse
FFA(18:1) 281.249 281.2486 282.2559 1.4 18:1 WT-HF, ob/ob-RC,
ob/ob-HF
FFA(18:2) 279.234 279.2330 280.2402 3.6 18:2 WT-HF
TAG(50:1) 850.783 850.7858 832.7520 −3.1 16:0/16:0/18:1 yes 551.5, 577.5 ob/ob-RC
TAG(50:2) 848.772 848.7702 830.7363 2.1 16:0/16:1/18:1 yes 549.5, 575.5,
577.5
ob/ob-RC, ob/ob-HF
TAG(52:2) 876.801 876.8015 858.7676 −0.6 16:0/18:1/18:1 yes 577.5, 603.5 WT-HF, ob/ob-RC,
ob/ob-HF
TAG(52:3) 874.788 874.7858 856.7520 2.5 16:1/18:1/18:1 and
16:0/18:1/18:2
yes 575.5, 577.5,
601.5, 603.5
WT-HF, ob/ob-RC,
ob/ob-HF
TAG(52:4) 872.7698 872.7702 854.7363 0.5 16:0/18:2/18:2 and
16:1/18:1/18:2
yes 573.5, 575.5,
599.5, 601.5
WT-HF, ob/ob-HF
TAG(54:3) 902.816 902.8171 884.7833 −1.2 18:1/18:1/18:1 yes 603.5 ob/ob-RC, ob/ob-HF
TAG(54:4) 900.801 900.8015 882.7676 −0.6 18:1/18:1/18:2 yes 601.5, 603.5 WT-HF, ob/ob-HF
Human
FFA(16:0) 255.234 255.2330 256.2402 3.1 16:0 NASHb
FFA(18:1) 281.249 281.2486 282.2559 2.8 18:1 steatosis, NASH
FFA(18:2) 279.232 279.2330 280.2402 2.5 18:2 NASH
TAG(48:1) 822.754 822.7545 804.7207 −1.2 16:0/16:0/16:1 yes 549.5, 551.5 NASH
TAG(50:1) 850.783 850.7858 832.7520 −3.1 16:0/16:0/18:1 yes 551.5, 577.5 steatosis, NASH
TAG(50:2) 848.770 848.7702 830.7363 −0.5 16:0/16:1/18:1 and
16:0/16:0/18:2
yes 575.5, 577.5,
549.5, 551.5
steatosis, NASH
TAG(52:2) 876.799 876.8015 858.7676 −3.4 16:0/18:1/18:1 yes 577.5, 603.5 steatosis, NASH
TAG(52:3) 874.784 874.7858 856.7520 −1.6 16:1/18:1/18:1 and
16:0/18:1/18:2
yes 575.5, 577.5,
601.5, 603.5
steatosis, NASH
TAG(54:3) 902.813 902.8171 884.7833 −4.4 18:1/18:1/18:1 yes 603.5 steatosis
aSigniﬁcant increase in lipid species relative to control group (“WT-RC” in mouse study; “normal” in human study). bNASHsigniﬁcantly
increased lipid species in “NASH” group relative to “normal”; NASHsigniﬁcantly increased lipid species in “NASH” group relative to both
“normal” and “steatosis” groups.
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order to address this, we prepared an IS mix, consisting of
isotopically labeled compounds covering the major classes of
lipids. This mix was incorporated into the LESA extraction
solvent, and internal standards of the appropriate class were
used to normalize peak intensities for lipids of interest.
Five areas were sampled per tissue slice, and three biological
replicates analyzed per animal group. The relative standard
deviation (CV) of analyte/IS peak intensity ratios for technical
replicates across a single tissue slice ranged from 5% to 25%,
with typical values of 11% for PCs and TAGs in positive ion
mode and 17% for FFAs in negative ion mode (Figure 3A−C).
Group means for analytes normalized to IS were compared for
those PCs, TAGs, and FFAs that were identiﬁed as important
by the multivariate analysis (Figure 3D−F). Interestingly, there
was no signiﬁcant diﬀerences found between animal groups for
PCs (Figure 3D). In contrast, signiﬁcant diﬀerences in TAG
species were noted across groups (Figure 3E, Table 2). We
conﬁrmed our previous observation that shorter chain TAGs
(50−52 C), with saturated and monounsaturated acyl chains,
tended to be highest in the ob/ob-RC group. TAGs with greater
degree of unsaturation and longer chain length (52−54 C)
tended to be most increased in WT-HF and ob/ob-HF groups.
FFA(18:1) was signiﬁcantly increased in all three NAFLD
groups, whereas FFA(18:2) was signiﬁcantly increased in the
HF-fed groups only (Figure 3F, Table 2).
LESA−MS Distinguishes Severity of Human NAFLD.
We applied our validated approach to thin slices of human liver
tissue, which ranged from no disease (normal), to simple
steatosis, and NASH (Figure 4). In addition to diﬀerentiating
normal and diseased tissue, we sought to establish whether
LESA−MS could be used to distinguish simple steatosis and
NASH. We therefore sampled multiple points across each
tissue slice from the three groups using LESA−MS and
examined the generated mass spectra (Figure 4A−B). In
positive ion mode, the most abundant ion for normal liver was
m/z 760.584 (PC(34:1) [M + H]+) (Figure 4A). In contrast,
NAFLD liver with either steatosis or NASH had signiﬁcantly
higher proportion of TAG species, with the most abundant ion
m/z 876.799 (TAG(52:2) [M + NH4]
+, fatty acid composition
16:0/18:1/18:1, Table 2). In negative ion mode, the most
intense ion in all three sample groups was m/z 281.249
(FFA(18:1) [M − H]−); however, the relative proportion of
18:1 compared to other fatty acid species appeared to increase
with steatosis and NASH (Figure 4B).
We used multivariate statistics to analyze the LESA−MS
spectra from each group. First, we compared normal versus
NAFLD (both simple steatosis and NASH) using OPLS-DA
(R2 = 0.72, Q2 = 0.86, CV-ANOVA p < 0.001; Figure 4C).
Similar to the mouse study, normal liver tissue was
characterized by a relative increase in PCs, whereas NAFLD
liver had increased TAGs and MUFA. Next, we compared liver
tissue with either simple steatosis or more severe NASH
(Figure 4D). These two groups were well-described by an
OPLS-DA model (R2 = 0.54, Q2 = 0.79, CV-ANOVA p <
0.001). Liver samples with NASH had a relative increase in
shorter chain TAGs, with fewer double bonds (e.g.,
TAG(50:2); fatty acid composition 16:0/16:1/18:1 or 16:0/
16:0/18:2, Table 2). In contrast, those with simple steatosis had
Figure 2. Lipid proﬁle distinguishes healthy and fatty liver in the mouse. Wild-type (WT) and ob/ob mice were fed a regular chow (RC) or high-fat
(HF) diet. Liver tissue from the four groups were stained with H&E (A; ×50), revealing increased fat accumulation (steatosis) in ob/ob and HF-fed
mice, compared to control (WT-RC). LESA−MS and principal components analysis (PCA) were used to compare the hepatic lipid proﬁles across
the four groups (N = 3 biological replicates per group; ﬁve repeat extractions per sample). The PCA scores (B) and corresponding loadings (C) plot
reveal that the four groups can be distinguished based on their hepatic lipid proﬁles. An OPLS-DA model was constructed to compare control (WT-
RC) liver with the three NAFLD groups (WT-HF, ob/ob-RC, ob/ob-HF) (D), revealing a relative increase in triacylglyceride (TAG) species and free
fatty acid (FFA) 18:1 in the diseased samples compared to the control group (E).
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increased TAGs with longer carbon chains, and a greater degree
of unsaturation (e.g., TAG(54:4); fatty acid composition 18:1/
18:1/18:2, Table 2). Furthermore, an increase in FFA(16:0)
and FFA(18:1) was observed in NASH, compared to steatosis.
We next employed our semiquantitative approach to
determine which of these lipids were signiﬁcantly changed by
NAFLD progression. We sampled ﬁve diﬀerent areas per tissue
slice, and three biological replicates were measured per group.
Similar to the ﬁndings in the mouse study, no signiﬁcant
changes in PCs were found across patient groups (Figure 4E).
As anticipated, signiﬁcant increases in TAG species and FFAs
were noted for samples with simple steatosis, and NASH
compared to normal controls (Figure 4E, Table 2). Of
particular note are those species which diﬀerentiate steatosis
and NASH [TAG(50:1), TAG(50:2), TAG(52:2), TAG(52:3),
FFA(18:1), FFA(18:2), and FFA(16:0)].
How Does LESA−MS Compare to Traditional Tools?
We compared the data obtained from LESA−MS (Figure 5A)
with traditional techniques, namely, LC−MS (Figure 5B) and
MALDI-MSI (Figure 5C). While LESA−MS is a surface
sampling tool, prior to LC−MS analysis lipids are extracted
from homogenized liver tissue. These lipid extracts are injected
onto a chromatographic column and separated by their relative
aﬃnities toward the mobile and stationery phases, followed by
MS detection (Figure 5B). We analyzed tissue extracts from the
WT-HF mouse group by LC−MS in both positive and negative
ion mode. A similar number and identity of lipid species were
detected for both LESA−MS and LC−MS.
Next, we analyzed a tissue slice from the WT-HF group using
MALDI-MSI. In order to assist ionization, a matrix is ﬁrst
deposited onto the tissue surface. The average spectra in
positive ion mode revealed predominantly TAGs, PCs, and
their fragmentation products (Figure 5C), whereas negative ion
mode was characterized by PIs, PEs, and FFAs. The overall
coverage of lipid classes and the number of diﬀerent lipid
species identiﬁed was substantially lower than for LESA−MS
and LC−MS, which utilize electrospray ionization (ESI).
However, MALDI-MSI has excellent spatial resolution (here
50 μm), allowing the generation of images which reveal the
distribution of individual lipid species across the tissue slice. For
example, PC(34:2) [M + K]+ is shown to be distributed in the
periportal zone (the area immediately surrounding portal veins)
of the liver (Figure 5C, inset). In contrast, LESA−MS has a
spatial resolution equivalent to the size of the solvent droplet in
contact with the sample. To assess this, we analyzed a tissue
slice by LESA. We subsequently coated this in matrix and
reanalyzed the tissue section by MALDI-MSI (Figure 5D). The
resulting ion image suggested a droplet diameter of 1.5−2
mmlarger than zonal diﬀerences of lipids across the liver
slice.
Next, we analyzed three samples from each of the four mouse
groups using LC−MS, following lipid extraction from
homogenized tissue. We performed PCA on the resulting
lipid proﬁles to construct a model which accurately classiﬁed
samples according to their group (Figure 5E). The ﬁrst
principal component separated the WT-RC group from the
three NAFLD groups, whereas diet was the main factor in the
Figure 3. Normalization to internal standards reveal signiﬁcantly changed lipids. An isotopically labeled internal standard (IS) mix was incorporated
into the LESA extraction solvent, allowing semiquantitative results, by comparing analyte/IS ratios across diﬀerent lipid classes (A−C). Multiple
extractions per tissue slice were performed and lipids of interest measured. Typical standard deviation of key lipid species across a single fatty liver
sample are shown for phosphatidylcholines (PC) (A), triacylglycerides (TAG) (B), and free fatty acids (FFA) (C). Data show mean ± standard
deviation (CV) of ﬁve repeat extractions across tissue slice. IS-normalized lipid abundances were compared across the diﬀerent groups (N = 3
animals per group, with ﬁve repeat extractions per sample) (D−F). No signiﬁcant diﬀerences were noted for PCs across the groups (D), whereas
speciﬁc TAGs (E) and FFAs (F) were signiﬁcantly diﬀerent across groups (ANOVA with Bonferroni correction; * P < 0.05, ** P < 0.01, *** P <
0.001). Data show mean ± SEM.
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second principal component. Model goodness-of-ﬁt and
prediction ability (R2 and Q2 values, respectively) were both
>0.9 and thus comparable to those obtained by LESA−MS
(Figure 2B). The loadings plot revealed the animal groups were
distinguished by similar lipid species to those identiﬁed in
LESA−MS (Figure 2C; Figure 5E). For instance, in both
approaches, WT-RC group are characterized by relative
increases in PC(34:2) and PC(36:2), WT-HF group by relative
increases in TAG(52:4) and FFA(18:2), ob/ob-RC by relative
increases in TAG(52:2) and FFA(18:1), and ob/ob-HF by a
relative increase in TAG(52:3) and TAG (54:4).
Similarly, three samples from each animal group were
analyzed by MALDI-MSI, and the resulting lipid proﬁles were
used to construct a PCA model (Figure 5E). While the four
animal groups were accurately clustered by their lipid proﬁles,
the model variation explained and prediction scores were lower
than for the other two analytical approaches (R2 = 0.64, Q2 =
0.48). The ﬁrst principal component separated the two dietary
groups (HF or RC), whereas the second principal component
was dominated by the genotype (WT or ob/ob). The loadings
plot revealed several diﬀerent lipids as being important for class
distinction, including PI(38:4) and PE(38:4) for the WT-HF
group and PI(36:4) and PI(34:2) for WT-RC. However, there
were also similarities with data from LC−MS and LESA−MS,
including PC(34:2) for WT-RC; FFA(18:1) for ob/ob-RC;
TAG(52:3) for ob/ob-HF (Figure 2C, Figure 5E). One
explanation for the lower model score, and diﬀerences in the
lipids identiﬁed as particularly important for the model, could
be a result of TAGs being ionized relatively poorly in MALDI
Figure 4. LESA−MS-determined presence and severity of NAFLD in human biopsies. Human liver tissue samples were analyzed by LESA−MS.
Example spectra in positive (A) and negative (B) ion mode are shown for normal, simple steatosis, and NASH liver, with H&E stained tissue (×100)
inset. An OPLS-DA model was constructed to compare normal vs NAFLD (both simple steatosis and NASH) liver (C). Similar to the mouse study,
a relative increase in triacylglycerides (TAG) and free fatty acid (FFA) 18:1 in NAFLD was noted, compared to a relative increase in
phosphatidylcholines (PC) in normal liver. Next, we used the LESA−MS-determined lipid proﬁles to discriminate between disease stage. Hepatic
lipid proﬁles in samples with simple steatosis or NASH were compared using OPLS-DA (D). This revealed a relative increase in short-chain TAG
species, FFA(16:0) and FFA(18:1), in NASH, compared to simple steatosis, which had a relative increase in longer chain TAGs. Using an internal
standard (IS) mix in the extraction solvent, analyte/IS ratios were measured across groups (N = 3 biological replicates per group, with ﬁve repeat
extractions per sample) (E). While PCs were not signiﬁcantly diﬀerent between groups, there were signiﬁcant diﬀerences noted between groups for
TAGs and FFAs, with a particular increase in TAGs containing short-chain fatty acids, FFA(16:0) and (18:1), in NASH. Data show mean ± SEM
(ANOVA with Bonferroni correction; * P < 0.05, ** P < 0.01, *** P < 0.001).
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(Figure 5C) compared to ESI (Figure 5A−B: LESA−MS and
LC−MS).
Overall, all techniques oﬀer a robust approach to open-
proﬁling lipidomics of liver tissue. While LESA−MS and
MALDI-MSI can be performed on tissue slices, MALDI-MSI
requires the deposition of a matrix on the tissue and LC−MS
requires extensive sample preparation to extract lipids from
tissue. Both LESA−MS and LC−MS provided excellent
coverage of lipid classes and species (Figure 5F) and are
rapid (here 1 min per LESA−MS spectrum and 10 min per
LC−MS chromatographic run), whereas performing MALDI-
MSI on a whole tissue slice can take 30 min to several hours,
depending on the size of sample to be analyzed. LC−MS,
however, oﬀers no spatial information, in contrast to MALDI-
MSI, where zonal diﬀerences of lipids were revealed.12 LESA−
MS has a spatial resolution of 1.5−2 mm (the size of the
droplet), which can be useful when distinct histological features
are suﬃciently large or well-separated in space. For instance
LESA−MS has been shown to be excellent for comparing lipid
proﬁles of large tumors to adjacent tissue.20 However, in liver
tissue, where distinction of tissue regions is less obvious,
LESA−MS has more limited use as a spatial mapping tool.
Finally, while MALDI-MSI and LESA−MS provide relative
quantitation, LC−MS remains the gold standard to perform
Figure 5. Comparison of LESA−MS with traditional techniques. We analyzed liver from wild-type (WT) and ob/ob mice fed a high-fat (HF) or
regular chow (RC) diet using LESA−MS (A), LC−MS (B), and MALDI-MSI (C). Representative positive ion spectra for WT-HF mice are shown
(A−C). While both LESA−MS and MALDI-MSI were performed on thin sections of liver tissue, LC−MS analysis was performed following
extraction of lipids from homogenized tissue. In LC−MS, lipids were separated by chromatography, prior to MS detection (B). Spatial distributions
of lipids were observed using MALDI-MSI (C, inset), which tends to induce more fragmentation than electrospray-formed ions (LESA−MS or LC−
MS). Species marked with asterisks were identiﬁed as phosphatidylcholine (PC) or triacylglyceride (TAG) fragments (C). A tissue slice analyzed by
LESA−MS was coated in matrix and reanalyzed using MALDI-MSI (D). Dashed white circles indicate LESA sampling regions and suggest the spatial
resolution provided by this LESA method is ∼1.5 mm2, larger than zonal diﬀerences in lipid distributions across liver tissue. Image shows PC(38:4)
[M + K]+ abundance (red and blue indicate highest and lowest ion intensities, respectively). Three samples per mouse group (WT-RC, WT-HF, ob/
ob-RC, ob/ob-HF) were analyzed by LC−MS or MALDI-MSI (E). Lipid proﬁles from the respective techniques were used to construct PCA models.
Corresponding loadings plots reveal the lipids driving the diﬀerentiation of the four groups. The typical number of lipids and lipid classes identiﬁed
were similar in LC−MS and LESA−MS, but greater than those identiﬁed using MALDI-MSI (F). Overall, the main advantages and limitations of
each technique are given.
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absolute quantitation, through the use of internal standards and
calibration standard curves. Semiquantitative results can be
achieved for LESA−MS, by incorporating isotopically labeled
internal standards into the extraction solvent. The advantages
and limitations of each technique are summarized in Figure 5F.
■ CONCLUSION
LESA−MS is shown to be a robust and discriminating approach
for determining NAFLD presence and severity in a set of
human liver biopsies. By extracting lipids directly from the
surface of thin tissue sections, rather than using extracts from
homogenized tissue, we can make use of limited material,
particularly critical given the nature of human tissue biopsies.
LESA−MS further oﬀers the opportunity to perform rapid
analyses with minimal sample preparation and acquisition time,
providing a high coverage of lipid classes, and without complete
consumption of the sample. Current diagnosis and grading of
NAFLD requires biopsy slices to be examined by a pathologist,
and therefore, LESA−MS is ideally suited to complement
traditional histology, with potential for “bench-to-bedside”
clinical applications.
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